Evidence map›Paper›PMID 41042627›Full record

ArticleDiabetes2025

Regulatory Roles of IGF2R in Insulin Secretion and Adaptive β-Cell Proliferation.

Jun Shirakawa, Dario F De Jesus, Takahiro Tsuno, Giorgio Basile, Ryota Inoue, Tomozumi Takatani, Akira Nishiyama, Erin R Okawa, Tomohiko Tamura, Yasuo Terauchi and 1 more

Abstract read
In one paragraph

Article in Diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jun ShirakawaIslet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA.ORCID 0000-0002-0822-8750
Dario F De JesusIslet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA.
Takahiro TsunoLaboratory of Diabetes and Metabolic Disorders, Institute for Molecular and Cellular Regulation (IMCR), Gunma University, Maebashi, Japan.
Giorgio BasileIslet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA.
Ryota InoueLaboratory of Diabetes and Metabolic Disorders, Institute for Molecular and Cellular Regulation (IMCR), Gunma University, Maebashi, Japan.
Tomozumi TakataniIslet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA.
Akira NishiyamaDepartment of Immunology, Graduate School of Medicine, Yokohama-City University, Yokohama, Japan.
Erin R OkawaIslet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA.
Tomohiko TamuraDepartment of Immunology, Graduate School of Medicine, Advanced Medical Research Center, Yokohama-City University, Yokohama, Japan.
Yasuo TerauchiDepartment of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama-City University, Yokohama, Japan.ORCID 0000-0002-8872-3697
Rohit N KulkarniIslet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA.ORCID 0000-0001-5029-6119

Funding

SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI ROHIT N. KULKARNI · 1986 to 2026
$50.5M
Role of IGF-1 and Insulin Receptors Beta-Cell SurvivalR01DK067536 · NIDDK · JOSLIN DIABETES CENTER · PI ROHIT N. KULKARNI · 2004 to 2026
$8.0M
Epitranscriptomics in human obesity and type 2 diabetesRC2DK139552 · NIDDK · JOSLIN DIABETES CENTER · PI Mengjie Chen, CHUAN HE · 2024 to 2026
$6.0M
Validation of small molecule 12-lipoxygenase inhibitors in metabolic diseaseR01DK105588 · NIDDK · UNIVERSITY OF CHICAGO · PI KULKARNI, ROHIT N., MIRMIRA, RAGHAVENDRA G · 2015 to 2024
$5.5M
Interrogating the role of m6A mRNA methylation in the aging of the β-cell and diabetesR00DK135927 · NIDDK · UNIVERSITY OF CHICAGO · PI Dario F De Jesus · 2025 to 2026
$498k
Interrogating the role of m6A mRNA methylation in the aging of the β-cell and diabetesK99DK135927 · NIDDK · JOSLIN DIABETES CENTER · PI F DE JESUS, DARIO · 2023 to 2024
$180k
AOU NIH HHS R01 DK067536AOU NIH HHS R01 DK105588AOU NIH HHS RC2 DK 139552Chugai Foundation for Innovative Drug Discovery ScienceDaiichi Sankyo Foundation of Life ScienceDiabetes Research and Wellness Foundation Endowed ChairJapan IDDM networkJapan Society for the Promotion of Science (B) 23H03324Japan Society for the Promotion of Science JPMXP0618217493Japan Society for the Promotion of Science JPMXP0622717006JST FOREST Program 24012821Naito FoundationNIDDK NIH HHS K99 DK135927NIDDK NIH HHS P30 DK036836NIDDK NIH HHS R00 DK135927NIDDK NIH HHS R01 DK067536NIDDK NIH HHS R01 DK105588NIDDK NIH HHS RC2 DK139552Taiju Life Social Welfare FoundationTakeda Science FoundationUehara Memorial Foundation
6 · The paper itself

Abstract

Insulin-like growth factor-2 receptor (IGF2R), also known as cation-independent mannose-6-phosphate receptor, is localized in cytosolic vesicles and is unique in its ability to transport enzymes to the lysosome and to clear IGF2 from the cell surface by acting as a scavenger receptor. To evaluate the direct role of IGF2R in β-cell biology, we undertook complementary in vitro knockdown and in vivo knockout approaches. A β-cell line with a stable knockdown of IGF2R (IGF2RKD) exhibited decreased glucose-induced insulin secretion and enhanced cell proliferation. Tamoxifen-inducible β-cell-specific IGF2R knockout mice exhibited impaired glucose tolerance and blunted insulin secretion after high-fat-diet loading that was likely secondary to reduced β-cell mass due to attenuated proliferation. β-cells with IGF2RKD had fewer autophagosomes after starvation and reduced expression of p62, LC3B, and ULK1. Aged mice also had impaired autophagy in βIGF2R-deficient β-cells. Reduced IGF2R function and N6-methyladenosine (m6A) mRNA methylation were observed in islets from both mouse and human type 2 diabetes. Taken together, these data point to IGF2R as an important regulator of insulin secretion, cell proliferation, and autophagy in mammalian β-cells. ARTICLE HIGHLIGHTS: The significance of insulin-like growth factor-2 receptor (IGF2R) in β-cells remains unclear. To assess the physiological role of IGF2R in β-cells, the effects of IGF2R deficiency in vivo and in vitro were investigated. IGF2R modulates insulin secretion, cell proliferation, and autophagy in β-cells. IGF2R plays a role in the regulation of β-cell biology.

Indexed as

Cell ProliferationInsulinInsulin-Secreting CellsInsulin SecretionReceptor, IGF Type 2AnimalsAutophagyHumansMaleMiceMice, KnockoutInsulinReceptor, IGF Type 2

Identifiers

PMID41042627
PMCPMC12645171

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.